source
- Lilly's amylin-Zepbound combo shows up to 23.3% weight loss in obesity-diabetes patients at EASD 2026Lilly presented new data on its amylin‑Zepbound combination at the European Association for the Study of Diabetes meeting in Milan. The trial focused on patients who have both obesity and type 2 di…
- Lilly uses indirect data to argue its oral GLP-1 pill may outperform Novo’s semaglutideEli Lilly’s weight‑loss drug Foundayo has seen a slower launch than expected, according to BMO Capital Markets, which noted the product is lagging behind competitors. To bolster its market case, L…